TME Pharma has entered a binding exclusive negotiation agreement with Japanese biotech company TMS Co., Ltd. for the global rights to NOX-A12, a drug targeting glioblastoma brain cancer. TMS will create a subsidiary to fund and advance clinical development, paying TME Pharma €150,000 for six months of exclusivity and potentially €10 million upfront plus over €100 million in milestones and royalties. The partnership aims to restart the Phase 2 GLORIA trial quickly, leveraging favorable biotech market conditions. NOX-A12 has FDA Fast Track and orphan drug designations, highlighting its potential in treating aggressive brain cancer.
TME Pharma's exclusive negotiation with TMS Co., Ltd. is presented here with Health-sector market data from Pluang. For readers following Health stocks, 105 of 150 US-listed Health-sector stocks rose while 42 fell as of Oct 29, 2026 14:11 WIB. Notable movers include CTXR at USD 0.54 with a 6.10% increase, TDOC at USD 7.29 up 5.96%, and BKD at USD 9.99 rising 4.83%.
DNO ASA, a Norwegian oil and gas company, announced a cash dividend of NOK 0.375 per share to be paid around November 17, 2026. Shareholders registered by November 9, 2026, will receive the dividend, with shares trading ex-dividend starting November ...
TGS ASA announced that its shares will be traded ex-dividend at NOK 1.45 per share starting October 29, 2026. This means investors buying the stock from this date will not receive the upcoming dividend payment. The dividend distribution follows appro...
Metaplex (MPLX) surged 36.62% on October 29, significantly outperforming the broader NFT sector, which rose 2.56%. This sharp rally followed a period of low trading activity but lacked a clear catalyst such as a project update or announcement. Metapl...
A data leak revealed records connecting 4,580 swap orders to public blockchain deposits, Monero destinations, and client IP addresses. This leak allows tracing transaction activity across networks by linking a public-chain deposit, the Monero exchang...
TME Pharma has entered a binding exclusive negotiation agreement with Japanese biotech TMS Co., Ltd. to develop and commercialize NOX-A12 for glioblastoma. TME Pharma receives €150,000 for exclusivity and expects around €10 million upfront plus over ...
